These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 28591284

  • 1. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.
    Sugimoto MAA, Toledo VPCP, Cunha MRR, Carregal VM, Jorge R, Leão P, Fialho SL, Silva-Cunha A.
    Arq Bras Oftalmol; 2017; 80(2):108-113. PubMed ID: 28591284
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab.
    Crul M, Zandvliet A, Moes JR, Veenbaas T, Smeets O.
    J Ocul Pharmacol Ther; 2019; 35(6):372-375. PubMed ID: 31259653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.
    Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, Kuo HK.
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure.
    Akbas S, Sahin A, Calis S, Oncel H, Capan Y.
    Pharmazie; 2018 Jul 01; 73(7):369-374. PubMed ID: 30001769
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions.
    Signorello L, Pucciarelli S, Bonacucina G, Polzonetti V, Cespi M, Perinelli DR, Palmieri GF, Pettinari R, Pettinari C, Fiorentini G, Vincenzetti S.
    Curr Pharm Biotechnol; 2014 Jul 01; 15(2):113-9. PubMed ID: 24953231
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Quality of bevacizumab compounded for intravitreal administration.
    Palmer JM, Amoaku WM, Kamali F.
    Eye (Lond); 2013 Sep 01; 27(9):1090-7. PubMed ID: 23788205
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab.
    Das T, Volety S, Ahsan SM, Thakur AK, Sharma S, Padhi TR, Basu S, Rao ChM.
    Clin Exp Ophthalmol; 2015 Jul 01; 43(5):466-73. PubMed ID: 25545882
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab.
    Schargus M, Kopp KT, Helbig C, Frings A, Winter G.
    Transl Vis Sci Technol; 2021 Aug 02; 10(9):21. PubMed ID: 34406342
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.
    Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF.
    Invest Ophthalmol Vis Sci; 2011 Feb 02; 52(2):1023-34. PubMed ID: 21051703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.